KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
This guideline cites 3 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2024
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. Kidney Int. 2024;105(3S):S71–S116.doi 10.1016/j.kint.2023.10.008
This guideline replaces the ANCA chapter of the 2021 glomerular-diseases document. Rituximab and cyclophosphamide are put on an equal footing for remission induction, the reduced-dose glucocorticoid taper from PEXIVAS becomes the default, and plasma exchange is demoted to a case-by-case option for very severe kidney involvement or alveolar haemorrhage. Avacopan enters as a glucocorticoid-sparing alternative. Rituximab is preferred for maintenance, with duration guided by relapse risk. The register's trials are grouped by treatment principle below.
Remission induction: rituximab vs. cyclophosphamide1
- 2010RAVE CoreNephrology · Glomerular · ANCA vasculitisIn 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.64% vs 53%Read →
Plasma exchange & glucocorticoid dosing1
- 2020PEXIVAS CoreNephrology · Glomerular · ANCA vasculitisIn 704 patients with severe ANCA-associated vasculitis, plasma exchange did not reduce death or end-stage kidney disease compared with no plasma exchange.HR 0.8695% CI 0.65-1.13Read →
Complement C5a-receptor inhibition: avacopan1
- 2021ADVOCATENephrology · Glomerular · ANCA vasculitisIn 331 patients with ANCA-associated vasculitis, the oral C5a-receptor antagonist avacopan improved sustained remission at week 52 compared with a tapering prednisone regimen.65.7% vs 54.9%Read →
Cited landmark trials not yet in the register6
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2007MEPEX
Plasma exchange in severe renal vasculitis — the positive trial PEXIVAS did not confirm.
- 2009CYCLOPS
Pulsed vs. daily oral cyclophosphamide: equal remission, lower cumulative dose, more relapses.
- 2010RITUXVAS
Rituximab-based induction in severe renal ANCA vasculitis.
- 2014MAINRITSAN
Rituximab superior to azathioprine for remission maintenance.
- 2024RITAZAREM
Rituximab beat azathioprine for maintenance after a relapse.
- 2021LoVAS
Reduced-dose glucocorticoid plus rituximab was non-inferior in non-severe disease.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.